Guselkumab is a human monoclonal IgG1λ antibody that selectively binds to the p19 subunit of interleukin 23 (IL-23) and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Guselkumab inhibits the release of proinflammatory cytokines and chemokines.

TREMFYA is an interleukin-23 blocker indicated for the treatment of adult patients with: moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy; active psoriatic arthritis.

Plaque Psoriasis: 100 mg administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter. Psoriatic Arthritis: 100 mg administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter. TREMFYA can be used alone or in combination with a conventional DMARD (e.g., methotrexate).

Most common (≥1%) adverse reactions associated with TREMFYA include upper respiratory infections, headache, injection site reactions, arthralgia, bronchitis, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

Serious hypersensitivity reactions to guselkumab or to any of the excipients.

Hypersensitivity Reactions: Serious hypersensitivity reactions, including anaphylaxis, may occur. Infections: TREMFYA may increase the risk of infection. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue TREMFYA until the infection resolves. Tuberculosis (TB): Evaluate for TB prior to initiating treatment with TREMFYA.